Novus Therapeutics begins dosing in otitis media drug trial - Drug Development Technology

Novus Therapeutics begins dosing in otitis media drug trial  Drug Development Technology

Novus Therapeutics has commenced dosing in a Phase IIa trial of OP0201 for the treatment of otitis media, an inflammatory disease affecting the middle ear.